Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 230.00
Bid: 233.00
Ask: 233.00
Change: -4.00 (-1.71%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 234.00
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

21 Nov 2023 07:00

RNS Number : 0496U
PureTech Health PLC
21 November 2023
 

21 November 2023

 

PureTech Health plc

 

Transaction in Own Shares

 

PureTech Health PLC (the "Company") announces that it has purchased the following number of its ordinary shares of one pence each through Jefferies International Limited ("Jefferies"), as part of its Share Buyback Programme, details of which were announced on 9 May 2022.

 

Date of purchase:

20 November 2023

Number of ordinary shares purchased:

50,034

Highest price paid per share:

174.60p

Lowest price paid per share:

171.40p

Volume weighted average price paid per share:

172.77p

 

PureTech intends to retain the purchased shares in treasury.

Following the above transaction, the Company will have 16,405,448 ordinary shares in treasury and has 273,062,711 ordinary shares in issue (excluding treasury shares). The total number of voting rights in the Company is therefore 273,062,711 which may be used by shareholders in their calculations to determine if they are required to notify their interest in, or a change to their interest in, PureTech Health plc under the FCA's Disclosure Guidance and Transparency Rules.

 

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018) (the Market Abuse Regulation), detailed information about the individual purchases is available below.

 

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com or connect with us on X, formerly known as Twitter, @puretechh.

 

Contact:

PureTech

Investor Relations

IR@puretechhealth.com

Individual Transactions

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

20/11/2023

08:04:02

534

172

XLON

00378899565TRLO0.1.1

20/11/2023

08:54:03

297

172.6

BATE

00378908143TRLO0.1.1

20/11/2023

09:02:41

36

172.6

BATE

00378909388TRLO0.1.1

20/11/2023

09:02:41

57

172.6

BATE

00378909387TRLO0.1.1

20/11/2023

09:02:41

206

172.4

CHIX

00378909390TRLO0.1.1

20/11/2023

09:02:41

124

172.6

BATE

00378909389TRLO0.1.1

20/11/2023

09:02:41

328

172.4

CHIX

00378909391TRLO0.1.1

20/11/2023

09:02:41

534

172.6

XLON

00378909392TRLO0.1.1

20/11/2023

09:02:41

534

172.6

XLON

00378909393TRLO0.1.1

20/11/2023

09:03:41

203

171.4

AQXE

00378909503TRLO0.1.1

20/11/2023

09:03:41

111

171.4

TRQX

00378909504TRLO0.1.1

20/11/2023

11:32:21

534

174

CHIX

00378924329TRLO0.1.1

20/11/2023

11:32:21

1068

174

XLON

00378924331TRLO0.1.1

20/11/2023

11:32:21

109

174

CHIX

00378924330TRLO0.1.1

20/11/2023

11:32:21

617

174

CHIX

00378924332TRLO0.1.1

20/11/2023

11:32:21

173

173.6

BATE

00378924334TRLO0.1.1

20/11/2023

11:32:21

111

173.6

TRQX

00378924336TRLO0.1.1

20/11/2023

11:32:21

111

173.6

TRQX

00378924335TRLO0.1.1

20/11/2023

11:32:21

32

173.6

BATE

00378924338TRLO0.1.1

20/11/2023

11:32:21

113

173.6

BATE

00378924337TRLO0.1.1

20/11/2023

11:32:21

29

173.6

BATE

00378924339TRLO0.1.1

20/11/2023

11:32:21

44

173.6

BATE

00378924340TRLO0.1.1

20/11/2023

11:32:21

514

173.6

BATE

00378924342TRLO0.1.1

20/11/2023

11:32:21

123

173.6

BATE

00378924341TRLO0.1.1

20/11/2023

11:32:21

190

174

XLON

00378924343TRLO0.1.1

20/11/2023

11:32:21

481

174

XLON

00378924344TRLO0.1.1

20/11/2023

11:32:22

203

174.2

AQXE

00378924345TRLO0.1.1

20/11/2023

12:21:45

441

174.2

CHIX

00378927764TRLO0.1.1

20/11/2023

12:21:47

558

174.2

XLON

00378927769TRLO0.1.1

20/11/2023

12:30:11

986

174.2

XLON

00378928241TRLO0.1.1

20/11/2023

12:38:02

234

173.2

BATE

00378928660TRLO0.1.1

20/11/2023

12:43:54

212

174

CHIX

00378929032TRLO0.1.1

20/11/2023

12:43:54

105

174

CHIX

00378929033TRLO0.1.1

20/11/2023

12:45:37

717

174.2

XLON

00378929154TRLO0.1.1

20/11/2023

13:01:33

218

174.6

XLON

00378930291TRLO0.1.1

20/11/2023

13:22:05

534

174.4

CHIX

00378932490TRLO0.1.1

20/11/2023

13:22:05

1068

174.4

XLON

00378932491TRLO0.1.1

20/11/2023

13:22:06

203

174.4

AQXE

00378932492TRLO0.1.1

20/11/2023

13:22:08

111

173.6

TRQX

00378932494TRLO0.1.1

20/11/2023

13:22:09

386

174.4

XLON

00378932495TRLO0.1.1

20/11/2023

13:53:23

198

172.8

XLON

00378936591TRLO0.1.1

20/11/2023

13:53:23

794

172.8

BATE

00378936592TRLO0.1.1

20/11/2023

13:53:23

870

172.8

XLON

00378936593TRLO0.1.1

20/11/2023

13:53:23

41

172.8

AQXE

00378936594TRLO0.1.1

20/11/2023

13:54:12

72

172.8

AQXE

00378936684TRLO0.1.1

20/11/2023

13:54:12

162

172.8

AQXE

00378936683TRLO0.1.1

20/11/2023

13:54:44

135

173.4

CHIX

00378936745TRLO0.1.1

20/11/2023

13:54:44

246

173.4

CHIX

00378936746TRLO0.1.1

20/11/2023

13:56:31

131

172.8

AQXE

00378936960TRLO0.1.1

20/11/2023

13:56:31

111

172.8

AQXE

00378936961TRLO0.1.1

20/11/2023

14:18:25

1602

173.4

XLON

00378940700TRLO0.1.1

20/11/2023

14:22:32

109

172.8

AQXE

00378941402TRLO0.1.1

20/11/2023

14:22:32

126

172.8

BATE

00378941403TRLO0.1.1

20/11/2023

14:40:42

5

172.8

BATE

00378951977TRLO0.1.1

20/11/2023

14:40:42

165

172.8

BATE

00378951976TRLO0.1.1

20/11/2023

14:41:03

369

172.8

CHIX

00378952147TRLO0.1.1

20/11/2023

14:41:03

218

172.8

BATE

00378952148TRLO0.1.1

20/11/2023

14:41:03

165

172.8

CHIX

00378952150TRLO0.1.1

20/11/2023

14:41:03

71

172.8

BATE

00378952149TRLO0.1.1

20/11/2023

14:41:03

534

172.8

CHIX

00378952151TRLO0.1.1

20/11/2023

14:41:03

111

172.8

TRQX

00378952153TRLO0.1.1

20/11/2023

14:41:03

443

172.8

BATE

00378952152TRLO0.1.1

20/11/2023

14:41:03

534

172.8

XLON

00378952156TRLO0.1.1

20/11/2023

14:41:03

62

172.8

TRQX

00378952154TRLO0.1.1

20/11/2023

14:41:03

49

172.8

TRQX

00378952155TRLO0.1.1

20/11/2023

14:41:03

8

172.6

XLON

00378952157TRLO0.1.1

20/11/2023

14:55:57

186

173.2

AQXE

00378959935TRLO0.1.1

20/11/2023

15:31:36

7

173

CHIX

00378978843TRLO0.1.1

20/11/2023

15:45:02

27

173

CHIX

00378985824TRLO0.1.1

20/11/2023

15:45:02

208

173

CHIX

00378985825TRLO0.1.1

20/11/2023

15:46:27

281

173

CHIX

00378986418TRLO0.1.1

20/11/2023

15:51:37

11

173

CHIX

00378988922TRLO0.1.1

20/11/2023

15:51:37

541

173

CHIX

00378988923TRLO0.1.1

20/11/2023

15:51:37

1602

173

XLON

00378988924TRLO0.1.1

20/11/2023

15:51:37

15

172.4

BATE

00378988925TRLO0.1.1

20/11/2023

15:51:37

80

172.4

BATE

00378988927TRLO0.1.1

20/11/2023

15:51:37

208

172.4

BATE

00378988926TRLO0.1.1

20/11/2023

15:51:37

211

172.4

BATE

00378988928TRLO0.1.1

20/11/2023

15:51:37

111

172.4

TRQX

00378988930TRLO0.1.1

20/11/2023

15:51:38

203

172.8

AQXE

00378988959TRLO0.1.1

20/11/2023

15:52:33

603

174

XLON

00378989573TRLO0.1.1

20/11/2023

15:52:33

328

174

XLON

00378989572TRLO0.1.1

20/11/2023

15:52:33

851

174

XLON

00378989574TRLO0.1.1

20/11/2023

15:52:35

270

174

CHIX

00378989586TRLO0.1.1

20/11/2023

15:52:37

436

174

XLON

00378989588TRLO0.1.1

20/11/2023

15:52:43

603

174

XLON

00378989610TRLO0.1.1

20/11/2023

15:53:28

514

173.2

BATE

00378989813TRLO0.1.1

20/11/2023

15:53:28

203

173

AQXE

00378989814TRLO0.1.1

20/11/2023

15:53:28

1062

173

CHIX

00378989815TRLO0.1.1

20/11/2023

15:53:28

29

173

TRQX

00378989816TRLO0.1.1

20/11/2023

15:53:28

1602

173.2

XLON

00378989817TRLO0.1.1

20/11/2023

15:58:52

534

172

CHIX

00378991309TRLO0.1.1

20/11/2023

15:58:52

111

172.2

TRQX

00378991310TRLO0.1.1

20/11/2023

15:58:52

1602

171.8

XLON

00378991311TRLO0.1.1

20/11/2023

15:59:32

15529

171.8

XLON

00378991589TRLO0.1.1

20/11/2023

16:03:10

223

171.8

XLON

00378993037TRLO0.1.1

20/11/2023

16:19:01

151

171.4

XLON

00378999384TRLO0.1.1

20/11/2023

16:19:01

386

171.4

XLON

00378999385TRLO0.1.1

20/11/2023

16:22:41

272

171.4

XLON

00379001249TRLO0.1.1

20/11/2023

16:29:55

514

171.8

BATE

00379005179TRLO0.1.1

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSFLFLTLLLIFIV
Date   Source Headline
2nd Nov 20204:35 pmRNSDirector/PDMR Shareholding
28th Oct 20207:00 amRNSPureTech Files Publicly for Nasdaq Listing
21st Oct 20201:03 pmRNSAkili Presents New Data on EndeavorRx at AACAP
20th Oct 20201:08 pmRNSVor Appoints Biotech Leader Matt Patterson to BOD
12th Oct 20201:00 pmRNSNew Vedanta VE202 Data Presented at UEG Week
7th Oct 20201:03 pmRNSAkili Adds Award-Winning Marketing Leader as CMO
5th Oct 202012:00 pmRNSAlivio Awarded $3.3M from DoD to Advance ALV-304
1st Oct 20207:05 amRNSPureTech Appoints Biocon Founder Kiran Shaw to BOD
1st Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20202:00 pmRNSBARDA Awards Vedanta Up to $76.9M to Advance VE303
29th Sep 202012:00 pmRNSAlivio Adds Dr Harry Leider to Board of Directors
25th Sep 20204:35 pmRNSPrice Monitoring Extension
23rd Sep 20207:00 amRNSPureTech Nasdaq Listing Progresses
18th Sep 20204:41 pmRNSSecond Price Monitoring Extn
18th Sep 20204:35 pmRNSPrice Monitoring Extension
18th Sep 202010:15 amRNSPrice Monitoring Extension
16th Sep 20201:00 pmRNSVedanta Appoints Drug Development Leader as CMO
4th Sep 202012:42 pmRNSGelesis Presents Plenity Efficacy and Safety Data
4th Sep 202012:07 pmRNSSecond Price Monitoring Extn
4th Sep 202012:02 pmRNSPrice Monitoring Extension
3rd Sep 202012:02 pmRNSPrice Monitoring Extension
28th Aug 20204:40 pmRNSSecond Price Monitoring Extn
28th Aug 20204:36 pmRNSPrice Monitoring Extension
27th Aug 20207:00 amRNSHalf-year Report
26th Aug 20201:02 pmRNSVor Appoints John King as Chief Commercial Officer
26th Aug 202012:40 pmRNSPRTC Receives $100M from Founded Entity Shares
26th Aug 202012:08 pmRNSPublication of Shareholder Circular
25th Aug 20202:05 pmRNSSonde Makes Acquisition in Vocal Biomarker Space
6th Aug 20207:00 amRNSNotice of Results
5th Aug 20207:00 amRNSPureTech to Present at Wedbush PacGrow Conference
3rd Aug 20207:00 amRNSTotal Voting Rights
30th Jul 20201:02 pmRNSVor Appoints Life Science Leader to BOD
30th Jul 202012:07 pmRNSSecond Price Monitoring Extn
30th Jul 202012:02 pmRNSPrice Monitoring Extension
21st Jul 202012:08 pmRNSSecond Price Monitoring Extn
21st Jul 202012:02 pmRNSPrice Monitoring Extension
17th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20201:04 pmRNSVor Appoints Biotech Finance Leader to BOD
14th Jul 20201:04 pmRNSVor Names Oncology Drug Development Expert as CMO
8th Jul 20201:32 pmRNSSonde Launches Voice Health Screening for COVID-19
8th Jul 202012:02 pmRNSPrice Monitoring Extension
7th Jul 202012:03 pmRNSPureTech’s Vor Raises $110M Series B Financing
6th Jul 20207:01 amRNSHolding(s) in Company
6th Jul 20207:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSTotal Voting Rights
23rd Jun 20201:48 pmRNSKaruna Positive FDA End of Phase 2 Meeting
23rd Jun 20207:00 amRNSAkili Gets European Approval to Market EndeavorRx
22nd Jun 20202:00 pmRNSPRTC Presents New Immuno-oncology Data at AACR
22nd Jun 20207:00 amRNSPDMR Notification RSU Vesting
18th Jun 202012:01 pmRNSGelesis China Deal $35M and up to $388M milestones

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.